Pelican Acquisition's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Pelican Acquisition (PELIU) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Peer Data As of Q3 2025
API endpoints for this dataset
https://api.csimarket.com/api/v1/companies/PELIU/competitors
https://api.csimarket.com/api/v1/companies/PELIU/relationships
https://api.csimarket.com/api/v1/companies/PELIU/similar
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Connect Your AI Assistant
Pelican Acquisition's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Pelican Acquisition Corporation | - | - | - | Yes |
| High-Confidence Competitors (35) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
PELIU Stock Performance relative to its Competitors
PELIU
Competitors (weighted)
Percent change over the selected range
PELIU Stock Performance relative to High-Confidence Competitors
PELIU
High-Confidence Competitors (equal-weighted, 36)
Percent change over the selected range
Pelican Acquisition's Comment on Competition and Industry Peers
Prior to entering into the Business Combination Agreement with Greenland Exploration Limited and March GL Company, the company competed with various entities, including blank check companies, private equity firms, venture capital funds, leveraged buyout funds, and operating companies pursuing strategic acquisitions. These competitors often possess greater financial, technical, and other resources. The company recognized that the requirement to acquire target businesses with an aggregate fair market value of at least 80% of assets held in trust, along with potential dilution from outstanding rights and securities, may have made it a less attractive transaction partner compared to certain competitors. Following the Business Combination, the combined company is expected to operate in a competitive industry with intense competition from existing and future competitors, without assurance of sufficient resources or competitive advantages to compete effectively. Prior to the agreement, the company conducted due diligence, including meetings with management, review of business plans and financial information, and legal and operational assessments.
Competitor data is not yet available for Pelican Acquisition.
Pelican Acquisition's Competitors Named by the Company
Competitive relationships identified from Pelican Acquisition reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Medpace Holdings Inc | Company report | 85% |
| Quanterix Corporation | Company report | 85% |
| Agilent Technologies inc | Company report | 85% |
| Twist Bioscience Corporation | Company report | 85% |
| Ingersoll Rand Inc | Company report | 85% |
| Quidelortho Corp | Company report | 85% |
| Cytek Biosciences Inc | Company report | 85% |
| Guardant Health Inc | Company report | 85% |
| Azenta Inc | Company report | 85% |
| Atlantic International Corp | Company report | 85% |
| Icon Plc | Company report | 85% |
| Iqvia Holdings Inc | Company report | 85% |
| Dlh Holdings Corp | Company report | 85% |
| Genetic Technologies Limited | Company report | 85% |
| Palisade Bio Inc | Company report | 85% |
| Greenland Exploration Limited | Company report | 85% |
| March GL Company | Company report | 85% |
| Nautilus Biotechnology Inc | Company report | 85% |
| Waters Corporation | Company report | 85% |
| Mirion Technologies Inc | Company report | 85% |
| Galera Therapeutics Inc | Company report | 85% |
| 908 Devices inc | Company report | 85% |
| Quantum si Incorporated | Company report | 85% |
| Maxcyte inc | Company report | 85% |
| Sophia Genetics Sa | Company report | 85% |
| Volitionrx Limited | Company report | 85% |
| Yeti Holdings Inc | Company report | 85% |
| Caredx Inc | Company report | 85% |
| SQL | Company report | 85% |
| Societal Cdmo Inc | Company report | 85% |
| Singular Genomics Systems Inc | Company report | 85% |
| Telesis Bio Inc | Company report | 85% |
| Emergent Biosolutions Inc | Company report | 85% |
| Auburn National Bancorporation Inc | Company report | 85% |
| Accelerate Diagnostics Inc | Company report | 85% |
| Idex Corp | Company report | 85% |
| WEED, INC. | Company report | 85% |
| Bio techne Corp | Company report | 85% |
| Bio rad Laboratories Inc | Company report | 85% |
| Us Nuclear Corp | Company report | 85% |
| Harvard Bioscience Inc | Company report | 85% |
| Veracyte Inc | Company report | 85% |
| Cue Health Inc | Company report | 85% |
| Evotec Se | Company report | 85% |
| Catalent Inc | Company report | 85% |
| Mettler toledo International Inc | Company report | 85% |
| Danaher Corporation | Company report | 85% |
| Steris Plc | Company report | 85% |
| 10x Genomics Inc | Company report | 85% |
| Cryoport inc | Company report | 85% |
| Qiagen N v | Company report | 85% |
| Standard Biotools Inc | Company report | 85% |
| Charles River Laboratories International inc | Company report | 85% |
| Illumina Inc | Company report | 85% |
| Pacific Biosciences Of California Inc | Company report | 85% |
| Revvity Inc | Company report | 85% |
| Repligen Corp | Company report | 85% |
| Maravai Lifesciences Holdings Inc | Company report | 85% |
| Abbott Laboratories | Company report | 85% |
| West Pharmaceutical Services Inc | Company report | 85% |
| American Bio Medica Corporation | Company report | 85% |
| Prophase Labs Inc | Company report | 85% |
| Cardinal Health Inc | Company report | 85% |
| Nanostring Technologies Inc | Company report | 85% |
| Corning Inc | Company report | 85% |
| Catheter Precision Inc | Company report | 85% |
| Bruker Corporation | Company report | 85% |
| Biomerica Inc | Company report | 85% |
| Qhslab Inc | Company report | 85% |
| 3m Company | Company report | 85% |
| Enzo Biochem Inc | Company report | 85% |
| Avantor Inc | Company report | 85% |
| Guided Therapeutics Inc | Company report | 85% |
| Lantheus Holdings Inc | Company report | 85% |
| Alpha Teknova Inc | Company report | 85% |
| Varian Medical Systems Inc | Company report | 85% |
| Somalogic Inc | Company report | 85% |
| Orasure Technologies Inc | Company report | 85% |
| Neogen Corporation | Company report | 85% |
| Psychemedics Corporation | Company report | 85% |
| Steris Plc | Company report | 85% |
| Astrotech Corp | Company report | 85% |
| Becton Dickinson And Company | Company report | 85% |
| Escalon Medical Corp | Company report | 85% |
| Quest Diagnostics Inc | Company report | 85% |
| Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter ___ | Company report | 85% |
| Johnson and Johnson | Company report | 85% |
Competitor Evidence Detail
Company report basis, confidence, active dates and source counts for Pelican Acquisition's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.